{"title":"Bispecific Antibody Therapy for Relapsed Lymphoma","authors":"Michael E. Williams","doi":"10.1056/NEJM-JW.NA54216","DOIUrl":null,"url":null,"abstract":"Bispecific therapeutic monoclonal antibodies are an emerging treatment option for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and multiple","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":"293 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEJM Journal Watch","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/NEJM-JW.NA54216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Bispecific therapeutic monoclonal antibodies are an emerging treatment option for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and multiple
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
